Cargando…
Patient-reported outcome and quality of life research policy: Japan Clinical Oncology Group (JCOG) policy
Assessments of patient-reported outcomes and health-related quality of life in cancer clinical trials have been increasingly emphasized recently because patient and public involvement in cancer treatment development has been promoted by regulatory authorities and academic societies. To assess patien...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9991489/ https://www.ncbi.nlm.nih.gov/pubmed/36702740 http://dx.doi.org/10.1093/jjco/hyad007 |
_version_ | 1784902166642688000 |
---|---|
author | Ishiki, Hiroto Kikawa, Yuichiro Terada, Mitsumi Mizusawa, Junki Honda, Michitaka Iwatani, Tsuguo Mizutani, Tomonori Mori, Keita Nakamura, Naoki Miyaji, Tempei Yamaguchi, Takuhiro Ando, Masahiko Nakamura, Kenichi Fukuda, Haruhiko Kiyota, Naomi |
author_facet | Ishiki, Hiroto Kikawa, Yuichiro Terada, Mitsumi Mizusawa, Junki Honda, Michitaka Iwatani, Tsuguo Mizutani, Tomonori Mori, Keita Nakamura, Naoki Miyaji, Tempei Yamaguchi, Takuhiro Ando, Masahiko Nakamura, Kenichi Fukuda, Haruhiko Kiyota, Naomi |
author_sort | Ishiki, Hiroto |
collection | PubMed |
description | Assessments of patient-reported outcomes and health-related quality of life in cancer clinical trials have been increasingly emphasized recently because patient and public involvement in cancer treatment development has been promoted by regulatory authorities and academic societies. To assess patient experiences during and after cancer treatment, there is interest in implementing patient-reported outcome and health-related quality of life assessments into cancer clinical trials. The Japan Clinical Oncology Group quality of life ad hoc committee previously created a version of the Quality of Life Assessment Policy in 2006. Recently, there has been increasing demand from Japan Clinical Oncology Group researchers to assess patient-reported outcome/health-related quality of life in clinical trials. Although guidelines are available regarding planning and reporting clinical trials that include patient-reported outcome/health-related quality of life as an endpoint, there are still issues regarding the lack of consensus on standardized methods for analysing and interpreting the results. Hence, it was considered necessary to reorganize the Japan Clinical Oncology Group patient-reported outcome/quality of life research committee and to revise the former patient-reported outcome/quality of life research policy to promote patient-reported outcome/health-related quality of life research in future Japan Clinical Oncology Group trials. The purpose of this Japan Clinical Oncology Group patient-reported outcome/quality of life research policy is to define patient-reported outcome/health-related quality of life research and provide guidelines for including patient-reported outcome/health-related quality of life as an endpoint in Japan Clinical Oncology Group trials. |
format | Online Article Text |
id | pubmed-9991489 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-99914892023-03-08 Patient-reported outcome and quality of life research policy: Japan Clinical Oncology Group (JCOG) policy Ishiki, Hiroto Kikawa, Yuichiro Terada, Mitsumi Mizusawa, Junki Honda, Michitaka Iwatani, Tsuguo Mizutani, Tomonori Mori, Keita Nakamura, Naoki Miyaji, Tempei Yamaguchi, Takuhiro Ando, Masahiko Nakamura, Kenichi Fukuda, Haruhiko Kiyota, Naomi Jpn J Clin Oncol Review Article (Invited) Assessments of patient-reported outcomes and health-related quality of life in cancer clinical trials have been increasingly emphasized recently because patient and public involvement in cancer treatment development has been promoted by regulatory authorities and academic societies. To assess patient experiences during and after cancer treatment, there is interest in implementing patient-reported outcome and health-related quality of life assessments into cancer clinical trials. The Japan Clinical Oncology Group quality of life ad hoc committee previously created a version of the Quality of Life Assessment Policy in 2006. Recently, there has been increasing demand from Japan Clinical Oncology Group researchers to assess patient-reported outcome/health-related quality of life in clinical trials. Although guidelines are available regarding planning and reporting clinical trials that include patient-reported outcome/health-related quality of life as an endpoint, there are still issues regarding the lack of consensus on standardized methods for analysing and interpreting the results. Hence, it was considered necessary to reorganize the Japan Clinical Oncology Group patient-reported outcome/quality of life research committee and to revise the former patient-reported outcome/quality of life research policy to promote patient-reported outcome/health-related quality of life research in future Japan Clinical Oncology Group trials. The purpose of this Japan Clinical Oncology Group patient-reported outcome/quality of life research policy is to define patient-reported outcome/health-related quality of life research and provide guidelines for including patient-reported outcome/health-related quality of life as an endpoint in Japan Clinical Oncology Group trials. Oxford University Press 2023-01-25 /pmc/articles/PMC9991489/ /pubmed/36702740 http://dx.doi.org/10.1093/jjco/hyad007 Text en © The Author(s) 2023. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permission@oup.com. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Review Article (Invited) Ishiki, Hiroto Kikawa, Yuichiro Terada, Mitsumi Mizusawa, Junki Honda, Michitaka Iwatani, Tsuguo Mizutani, Tomonori Mori, Keita Nakamura, Naoki Miyaji, Tempei Yamaguchi, Takuhiro Ando, Masahiko Nakamura, Kenichi Fukuda, Haruhiko Kiyota, Naomi Patient-reported outcome and quality of life research policy: Japan Clinical Oncology Group (JCOG) policy |
title | Patient-reported outcome and quality of life research policy: Japan Clinical Oncology Group (JCOG) policy |
title_full | Patient-reported outcome and quality of life research policy: Japan Clinical Oncology Group (JCOG) policy |
title_fullStr | Patient-reported outcome and quality of life research policy: Japan Clinical Oncology Group (JCOG) policy |
title_full_unstemmed | Patient-reported outcome and quality of life research policy: Japan Clinical Oncology Group (JCOG) policy |
title_short | Patient-reported outcome and quality of life research policy: Japan Clinical Oncology Group (JCOG) policy |
title_sort | patient-reported outcome and quality of life research policy: japan clinical oncology group (jcog) policy |
topic | Review Article (Invited) |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9991489/ https://www.ncbi.nlm.nih.gov/pubmed/36702740 http://dx.doi.org/10.1093/jjco/hyad007 |
work_keys_str_mv | AT ishikihiroto patientreportedoutcomeandqualityofliferesearchpolicyjapanclinicaloncologygroupjcogpolicy AT kikawayuichiro patientreportedoutcomeandqualityofliferesearchpolicyjapanclinicaloncologygroupjcogpolicy AT teradamitsumi patientreportedoutcomeandqualityofliferesearchpolicyjapanclinicaloncologygroupjcogpolicy AT mizusawajunki patientreportedoutcomeandqualityofliferesearchpolicyjapanclinicaloncologygroupjcogpolicy AT hondamichitaka patientreportedoutcomeandqualityofliferesearchpolicyjapanclinicaloncologygroupjcogpolicy AT iwatanitsuguo patientreportedoutcomeandqualityofliferesearchpolicyjapanclinicaloncologygroupjcogpolicy AT mizutanitomonori patientreportedoutcomeandqualityofliferesearchpolicyjapanclinicaloncologygroupjcogpolicy AT morikeita patientreportedoutcomeandqualityofliferesearchpolicyjapanclinicaloncologygroupjcogpolicy AT nakamuranaoki patientreportedoutcomeandqualityofliferesearchpolicyjapanclinicaloncologygroupjcogpolicy AT miyajitempei patientreportedoutcomeandqualityofliferesearchpolicyjapanclinicaloncologygroupjcogpolicy AT yamaguchitakuhiro patientreportedoutcomeandqualityofliferesearchpolicyjapanclinicaloncologygroupjcogpolicy AT andomasahiko patientreportedoutcomeandqualityofliferesearchpolicyjapanclinicaloncologygroupjcogpolicy AT nakamurakenichi patientreportedoutcomeandqualityofliferesearchpolicyjapanclinicaloncologygroupjcogpolicy AT fukudaharuhiko patientreportedoutcomeandqualityofliferesearchpolicyjapanclinicaloncologygroupjcogpolicy AT kiyotanaomi patientreportedoutcomeandqualityofliferesearchpolicyjapanclinicaloncologygroupjcogpolicy AT patientreportedoutcomeandqualityofliferesearchpolicyjapanclinicaloncologygroupjcogpolicy |